Registration for a live webinar on 'Innovations in antibiotic discovery: combating resistant infections' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Introduction
-
1. Editor's foreword
- Prof. Ann Daly
-
2. Introduction to drug metabolism enzymes
- Dr. Dennis Smith
- General factors affecting drug metabolism
-
3. General factors affecting drug metabolism: effect of physiological factors and disease 1
- Prof. Edward T. Morgan
-
4. General factors affecting drug metabolism: effect of physiological factors and disease 2
- Prof. Edward T. Morgan
-
5. Drug metabolism in liver disease
- Dr. Nathalie Zgheib
- Prof. Robert Branch
-
7. Prediction of pathways of drug metabolism
- Dr. Maurice Dickins
- Phase I metabolizing enzymes: cytochrome P450s
-
8. Cytochrome P450 1 family: the roles of 1A1, 1A2 and 1B1 in drug metabolism
- Prof. F. Peter Guengerich
-
9. CYP2 family
- Prof. Ann Daly
-
10. Why study the cytochrome P4503A (CYP3A) family?
- Dr. Erin Schuetz
-
11. Pharmacogenomics: an update
- Prof. Magnus Ingelman-Sundberg
- Phase I metabolizing enzymes: non-cytochrome P450s
-
12. Non-P450 oxidative metabolism: characteristics and drug substrates
- Dr. Christine Beedham
-
13. UDP-glucuronosyltransferases
- Prof. Abby Collier
- Phase II metabolizing enzymes: conjugating enzymes
-
14. Glutathione transferases
- Prof. Ralf Morgenstern
-
15. Arylamine N-acetyltransferases 1
- Prof. Edith Sim
-
16. Arylamine N-acetyltransferases 2
- Prof. Edith Sim
-
17. Arylamine N-acetyltransferases 3
- Prof. Edith Sim
-
18. Methyltransferases
- Prof. Richard Weinshilboum
-
19. Amino acid conjugation: mechanism and enzymology
- Dr. Kathleen Knights
- Clinical aspects
-
20. Clinical significance of enzyme induction and inhibition
- Prof. Kim Brøsen
-
21. Clinical importance of pharmacogenetic polymorphisms affecting drug metabolism
- Prof. Julia Stingl (formerly Kirchheiner)
- Latest Updates in the Field
-
22. Mammalian flavin-containing monooxygenases
- Prof. Allan Rettie
- Archived Lectures *These may not cover the latest advances in the field
-
23. Glucuronidation and the UDP - glucuronosyltransferases
- Prof. Peter Mackenzie
- Prof. John Miners
-
25. Catalytic cycle of cytochrome P450s
- Prof. Gordon Roberts
-
26. Drug metabolism and liver disease
- Prof. Robert Branch
-
27. Crystal structures of drug-metabolizing P450 monooxygenases
- Prof. Eric Johnson
-
28. Sulfation and human cytosolic sulfotransferases
- Prof. Charles Falany
-
29. Laboratory methods for the in vitro study of drug metabolism
- Dr. Charles Crespi
-
30. Clinical importance of pharmacogenetic polymorphisms affecting drug metabolism: psychopharmacology and pain
- Prof. Julia Stingl (formerly Kirchheiner)
-
32. Pharmacogenomics
- Prof. Magnus Ingelman-Sundberg
Printable Handouts
Navigable Slide Index
Topics Covered
- Genes and gene products
- Role of CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP2E1 in drug metabolism
- Regulation of gene expression
- Effect of genetic variation
- Clinically relevant polymorphisms
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Daly, A. (2016, March 1). Editor's foreword [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved May 13, 2025, from https://doi.org/10.69645/QJUB7766.Export Citation (RIS)
Publication History
Financial Disclosures
- Professor Ann Daly has no commercial/financial relationships to disclose.
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
As series editor, I would like to introduce you
to this series of talks.
These talks are aimed at
a wide audience interested
0:08
in drug metabolism, and
are particularly concerned
with human drug metabolism.
This series aims to provide
an introduction to the field,
as well as information
at research level.
The first section is
concerned with general factors
0:24
affecting drug metabolism, and
starts with an introductory talk
by Dennis Smith,
who's based at Pfizer.
We then follow with
five general talks,
including an overview on the nuclear
receptor superfamilies by Patrick
Maurel, talks on
physiological factors
and disease by Edward
Morgan and Robert Branch,
a talk on practical
approaches by Charles Crespi,
and a discussion of in silico
approaches by Maurice Dickins.
The next section is concerned
with phase I metabolism.
0:57
In phase I metabolism, cytochromes
P450 are the best studied and most
important enzyme family,
and most of this action
is taken up with discussion
of these enzymes.
We start with two talks on
structure and reaction of P450s
from Eric Johnson
and Gordon Roberts.
We then have talks on
individual isoforms.
Fred Guengerich considers the CYP1
family, I consider the CYP2 family,
and Erin Schuetz considers CYP3A.
There is an overview of the
pharmacogenetics of cytochrome P450
from Magnus Ingelman-Sundberg.
We then turn to non-P450
metabolism, and have a talk
on oxidative metabolism from
Christine Beedham and a talk
on esterases from Clement Furlong.
Section C is concerned with
phase II drug metabolism,